AB-Biotics Granted European Patent For Cholesterol-Lowering Probiotic

BARCELONA, SpainAB-Biotics was granted a patent by the European Patent Office (EPO) protecting compositions comprising the probiotic strains of Lactobacillus plantarum CECT 757, CECT 7528 and CECT 7529, found in its cholesterol-lowering probiotic AB-Life.

These new strains have probiotic features and are useful for the prevention and/or the treatment of hypercholesterolemia and cardiovascular disorders. The compositions comprising AB-Life strains can be pharmaceutical, veterinary and edible compositions. The patent also protects the administration of AB-Life with other cholesterol-lowering products, such as statins, which can reduce the necessary dosage of these drugs whose chronic consumption can cause side effects.

AB-Biotics has signed license agreements with different pharmaceutical companies to distribute AB-Life in Southeast Europe (through Inspharma), Germany (HLH Biopharma), Spain, Portugal (Lacer), South Korea (HanAll BioPharma), Mexico (Armstrong Laboratories), Brazil (Biolab) and Venezuela (Leti). AB-Biotics expects to license the product in new European markets in 2014.